DOCSLIB.ORG

Extrapulmonary Effects of Fenoterol and Salbutamol in Normal Subjects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Extrapulmonary Effects of Fenoterol and Salbutamol in Normal Subjects Letters to the editor 191 subjects there was an increase in bronchial Extrapulmonary effects the relative potency of fenoterol and salbuta- hyperresponsiveness only during the first mol, which requires dose-response curves in two weeks of the study, but by the end of of fenoterol and asthmatic subjects to ascertain relative bron- four weeks this increase had disappeared. In salbutamol in normal chodilator and systemic P2 receptor activity. Thorax: first published as 10.1136/thx.49.2.191-a on 1 February 1994. Downloaded from the study of Vathenen et al (ref 7) with eight subjects The 25 mg dose of atenolol in our study was asthmatic subjects it was observed that a chosen on the basis of it producing relatively (rebound) increase in hyperresponsiveness selective ,1 blockade. It is, however, well occurred, not whilst using the 13 agonist Newnham et al have attempted the difficult documented that atenolol displays dose but afterwards. In our own study (ref 14) task of trying to dissect relative and 12 related 02 blockade,'2 and so it is not, per- an increase in hyperresponsiveness was mediated cardiovascular responses to large haps, surprising that even a 25 mg dose pro- observed when using a.0 agonist in a selected doses of salbutamol and fenoterol in normal duced a degree of 02 antagonism. The im- group of 15 patients. These 15 patients were subjects with a low dose of atenolol (June portant point is that a comparable degree of selected on the condition that they had not 1993;48:656-8). There are two issues: firstly, attenuation occurred with heart rate and used any 1 agonists or 1 blockers for one year the comparative responses to similar doses of potassium responses, both of which have before the start of the study. They were part these agents by inhalation and, secondly, been shown to be 12 mediated.'-3 Indeed, this of a much larger group of 144 patients who, their selectivity at the receptor. occurred to the same extent with both feno- on average, did not show an increase in Newnham et al showed that salbutamol terol and salbutamol. bronchial hyperresponsiveness during the and fenoterol in doses of 1 mg and 3 mg from If fenoterol had stimulated cardiac ,1 use of the 13 agonist (ref 1, not presented in metered dose inhalers led to similar increases receptors to a greater degree than salbuta- in heart rate, distance, and tremor, the table). Looking at the presented table, it stroke mol, one would have predicted atenolol to seems that the more patients involved in with fenoterol causing a slightly greater fall have antagonised the chronotropic response these studies the less clear is the adverse in serum potassium concentration and a to fenoterol more than salbutamol. This was prognosis of bronchial hyperresponsiveness greater rise in systolic blood pressure than clearly not the case, with the percentage during the continuous use of a bronchodila- salbutamol. Their findings suggest smaller attenuation by atenolol at the 4 mg dose tor. This underlines our conclusion that only differences between higher doses of salbuta- being 14% for fenoterol and 16% for salbu- in subgroups of patients might the continu- mol and fenoterol on extrapulmonary effects tamol. The percentage attenuation of than other the ous use of a 12 adrenergic drug have an studies, whether the comparisons systolic blood pressure was also comparable adverse effect on bronchial hyperresponsive- have been Inade in vitro, in vivo, or in for both fenoterol (10%) and different fenoterol has salbutamol ness. The only exception seems to be the species.'2 Invariably (8%). Thus, whilst fenoterol may exhibit study of Sears and Taylor themselves (ref 3) been found to be more potent in large doses than salbutamol. intravenous greater P2 potency, there is no evidence for it with a relatively large number of 64 patients. Studies using being less selective in terms of relative car- preparations have found a 2-4 times greater However, this is the only study in which diac 11/12 receptor stimulation. It is also effect on heart rate with and this patients were allowed to use anti-inflamma- fenoterol, worth pointing out that in a study from has led to a tenfold difference in the concen- tory drugs as well as their bronchodilator Windom et a14 in asthmatic subjects there drugs. tration of intravenous solutions used rout- inely (500 salbutamol was no difference in either chronotropic or As Sears and Taylor have already acknow- pg/ml compared with systolic blood pressure responses to fenoterol ledged, the observed changes in hyper- 50 jg/ml fenoterol). The reasons for the dif- and salbutamol, in contrast with isoprenaline ferent of et are responsiveness are small. They are all findings Newnham al unclear. which produced greater effects, presumably The attempts to between 0-5 and 1-5 doubling doses of the by the authors dissect 13 adrenoceptor mediated.5 challenge test, which is virtually similar to relative and 12 effects have failed as they Our in vivo data are indeed supported by the repeatability of the challenge test' and is have shown that atenolol significantly at- in vitro data in human right atria,6 showing tenuates the 12 mediated effect on heart rate, therefore of doubtful clinical significance. that the relative pA2 values for practolol (1, http://thorax.bmj.com/ The purpose of writing our editorial was tremor, and serum potassium concentration. antagonist) and ICI 18 551 (12 antagonist) Other based on not to present a neutral position in this designs studies by Wellstein were 5-47 and 8-24 respectively, for antagon- important issue but to show that the general et aP' or Hall et al4 may enable such relative ism of the inotropic response to fenoterol. fear that exists among doctors and patients receptor specificity to be shown. Taken together we believe that the body of about the chronic use of bronchodilators evidence the J CRANE supports hypothesis that the does not seem to be justified by the data C BURGESS effects of fenoterol on the human heart are available at this moment. We did not, and do R BEASLEY predominantly caused by stimulation of car- not, doubt that bronchodilators probably Department of Medicine, Wellington School of Medicine, diac P2 receptors. have a (small) negative influence on the long Wellington, term prognosis of bronchial hyperrespons- New Zealand B J LIPWORTH on October 2, 2021 by guest. Protected copyright. iveness in certain groups of asthmatic D M NEWNHAM patients. Subgroup analyses of our own data C WONG D G McDEVITT Department of Medicine, Department of Clinical Pharmacology, have shown that especially allergic hyper- University of Otago, Ninewells Hospital and Medical School, responsive asthmatic patients seem to have Dunedin, Dundee DDI 9SY an increased progression of asthma with con- New Zealand tinuous use of a 1 agonist.2 Another import- ant issue which still has to be settled is what 1 Wong C, Pavord I, Williams J, Briton J, Tatters- 1 Lipworth BJ, Brown RA, McDevitt DG. Assess- field A. Bronchodilator, cardiovascular and ment of airways, tremor and chronotropic additional bronchodilator drug should be hypokalaemic effects of fenoterol, salbutamol responses to inhaled salbutamol in the quanti- used (and in what dose) when the patient and terbutaline in asthma. Lancet 1990; fication of 12 adrenoceptor blockade. BrJI Clin receives a combination of an anti-inflamma- 336:1396-9. Pharmacol 1989;28:95-102. tory drug and a bronchodilator. 2 Burgess C. An overview of experimental 2 Lipworth BJ, McFarlane LC, Coutie WJ, methods. In: Beasley C, Pearce N, eds. The McDevitt DG. Evaluation of metabolic re- role of beta receptor agonist therapy in asthma sponses to inhaled salbutamol in the measure- C P VAN SCHAYCK mortality. Boca Raton: CRC Press, 1993:127- ment of f adrenoceptor blockade. Eur J Clin C L A VAN HERWAARDEN 48. Pharmacol 1989;37:297-300. Departments of General Practice and Pulmonary 3 Wellstein A, Belz G, Palm D. Beta adrenoceptor 3 Hall JA, Petch MC, Brown MJ. Intracoronary Diseases, subtype binding activity in plasma and beta injections of salbutamol demonstrate the pres- Nijmegen University, blockade by propanolol and beta-I selective ence of functional 02 adrenoceptors in the PO Box 9101, bisoprolol in humans. Evaluation with Schild human heart. Circ Res 1989;65:546-53. 6500 HB Nijmegen, plots.JPharmacolExp Ther 1988;246:328-37. 4 Windom HH, Burgess CD, Siebers RWL, The Netherlands 4 Hall J, Petch M, Brown M. Intracoronary injec- Purdie GP, Pearce N, Crane J, et al. The pul- tions of salbutamol demonstrate the presence monary and extrapulmonary effects of inhaled of functional f2 adrenoceptors in the human ,B-agonists in patients with asthma. Clin 1 Cockcroft DW, Killian DN, Mellon JJA, Har- heart. Circ Res 1989;65:546-53. Pharmacol Ther 1990;48:296-301. greave FE. Bronchial rectivity to inhaled his- 5 Lipworth BJ, Tregaskis BF, McDevitt DG. tamine: a method and clinical survey. Clin Comparison of hypokalaemic, electrocardio- Allergy 1977;7:235-9. graphic and haemodynamic responses to 2 Schayck CP van, Kraak A, Dompeling E, Folger- AUTHORS' REPLY In reply to the letter of inhaled isoprenaline and salbutamol in young ing H, Weel C van. Dose-response relation- Crane et al there are some fundamental and elderly subjects. Eur J Clin Pharmacol ship between the decline in lung function and issues which, although discussed in the 1991;40:255-60. the daily dose of salbutamol and ipratropium 6 Wilson C, Lincoln C. 13-adrenoceptor subtypes paper, further bromide. Am Rev Respir Dis 1992;145(Sup- require clarification. in human, rat, guinea-pig and rabbit atria. J pl 2):A61. The purpose of our study was not to assess Cardiovasc Pharmacol 1984;6:1216-21..
Load more

Recommended publications
  • Application Number
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203975s000 SUMMARY REVIEW SUMMARY REVIEW OF REGULATORY ACTION Date: November 26, 2013 From: Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA Subject: Division Director Summary Review NDA Number: 20-3975 Applicant Name: GlaxoSmithKline Date of Submission: December 18, 2012 PDUFA Goal Date: December 18, 2013 Proprietary Name: Anoro Ellipta Established Name: Umeclidinium and vilanterol Dosage form: Inhalation Powder (inhaler contains 2 double-foil blister strips, each with 30 blisters containing powder for oral inhalation) Strength: Umeclidinium 62.5 mcg per blister and vilanterol 25 mcg per blister Proposed Indications: Maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) Action: Approval 1. Introduction GlaxoSmithKline (GSK) submitted this 505(b)(1) new drug application for use of Anoro Ellipta (umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder) for long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The proposed dose is one inhalation (umeclidinium 62.5 mcg and vilanterol 25 mcg) once daily. The application is based on clinical efficacy and safety studies. This summary review will provide an overview of the application, with a focus on the clinical efficacy and safety studies. 2. Background There are several drug classes available for the relief of airflow obstruction in patients with COPD. These include short- and long-acting beta-2 adrenergic agonists, short- and long-acting anticholinergics, combination products containing beta-2 adrenergic agonists and anticholinergics, combination of long-acting beta-2 adrenergic agonists and corticosteroids, methylxanthines, and phosphodiesterase-4 (PDE4) inhibitors.
    [Show full text]
  • Orciprenaline Sulphate (Alupent): Planned Withdrawal from the UK Market Following a Risk-Benefit Analysis
    MHRA PUBLIC ASSESSMENT REPORT Orciprenaline sulphate (Alupent): planned withdrawal from the UK market following a risk-benefit analysis November 2009 Executive summary 2 1. Introduction 3 2. Summary of data 3 2.1 Clinical pharmacology 3 2.2 Efficacy 3 2.3 Safety 4 3. Conclusions 8 4. References 9 5. Glossary 10 1 EXECUTIVE SUMMARY (Please note that this summary is intended to be accessible to all members of the public, including health professionals) Background The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency responsible for regulating the effectiveness and safety of medicines and medical devices in the UK. We continually review the safety of all medicines in the UK, and inform healthcare professionals and the public of the latest safety updates. In our Public Assessment Reports, we discuss the evidence for a safety issue with a particular drug or drug class, and changes made to the product information for the drug on the basis of this evidence, which will help safeguard public health. This MHRA Public Assessment Report discusses a review of the risks and benefits of a medicine called orciprenaline sulphate. Orciprenaline sulphate is available for oral administration as a syrup used to treat reversible airways obstructiona, which is a symptom of asthmab and chronic obstructive pulmonary diseasec. It acts on specific areas in the body called β- receptors, which relaxes the muscles used for breathing and opens the airways in the lungs. Orciprenaline sulphate was licensed in 1972 and is marketed in the UK under the brand name Alupent Syrup. As with any medicine, the use of orciprenaline sulphate may lead to adverse reactions (side-effects) in some individuals, which are described in the product information, including the patient information leaflet (see the Electronic Medicines Compendium (product information) website).
    [Show full text]
  • Case-Control Study Ofprescribed Fenoterol
    170 Thorax 1990;45:170-175 Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81 Thorax: first published as 10.1136/thx.45.3.170 on 1 March 1990. Downloaded from N Pearce, J Grainger, M Atkinson, J Crane, C Burgess, C Culling, H Windom, R Beasley Abstract A recent New Zealand case-control study,' A previous New Zealand case-control conducted by our group, tested the hypothesis study of asthma deaths in the 5-45 year that the unsupervised self administration of age group during 1981-3 found that pres- fenoterol by inhalation increases the risk of cription of fenoterol (by metered dose death from asthma. This hypothesis arose inhaler) was associated with an increased primarily from epidemiological evidence link- risk of death in patients with severe ing the sale of fenoterol to the epidemic of asthma. One major criticism ofthis study deaths from asthma that New Zealand has was that drug data for the cases and experienced since the late 1970s,' 2 and controls came from different sources. A experimental evidence that fenoterol is a less new case-control design has been used to selective beta2 agonist than salbutamol, the evaluate the same hypothesis, with a dif- most commonly used beta agonist.3 The possi- ferent set of asthma deaths, the same ble mechanisms ofaction remain to be clarified, source for drug information being used but several potential mechanisms are apparent; for both cases and controls. This depen- these depend on whether the association is with ded on identifying deaths from asthma long term use of fenoterol or use in the acute during 1977-81 from national mortality attack.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Salmeterol Enhances the Cardiac Response to Gene Therapy in Pompe Disease
    Salmeterol enhances the cardiac response to gene therapy in Pompe disease Sang-oh Han1, Songtao Li1, and Dwight D. Koeberl1* 1Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC *To whom correspondence should be addressed at: Box 103856, Duke University Medical Center, Durham, NC 27710. Running title: Small molecules for Pompe disease Page 2 ABSTRACT Enzyme replacement therapy (ERT) with recombinant human (rh) acid -glucosidase (GAA ) has prolonged the survival of patients. However, the paucity of cation-independent mannose-6- phosphate receptor (CI-MPR) in skeletal muscle, where it is needed to take up rhGAA, correlated with a poor response to ERT by muscle in Pompe disease. Clenbuterol, a selective 2 receptor agonist, enhanced the CI-MPR expression in striated muscle through Igf-1 mediated muscle hypertrophy, which correlated with increased CI-MPR (also the Igf-2 receptor) expression. In this study we have evaluated 4 new drugs in GAA knockout (KO) mice in combination with an adeno-associated virus (AAV) vector encoding human GAA, 3 alternative 2 agonists and dehydroepiandrosterone (DHEA). Mice were injected with AAV2/9-CBhGAA (1E+11 vector particles) at a dose previously found to be partially effective at clearing glycogen storage from the heart. Heart GAA activity was significantly increased by either salmeterol (p<0.01) or DHEA (p<0.05), in comparison with untreated mice. Furthermore, glycogen content was reduced in the heart by treatment with DHEA (p<0.001), salmeterol (p<0.05), formoterol (p<0.01), or clenbuterol (p<0.01) in combination with the AAV vector, in comparison with untreated GAA-KO mice.
    [Show full text]
  • Project Review
    PROJECT REVIEW ”Development of analytical methods for the quantitative determination of beta-agonists and determination of detection times after therapeutic use” Beta-agonists are substances frequently used for the treatment of asthma. These drugs are most frequently administered by inhalation of aerosol, powder or nebulised solution. Besides the main pharmacological effect, at higher doses, side effects of the use of these products result in anabolic action. Hence, beta-2- agonists might be misused for their stimulating effect on respiration and growth promoting action when administered in higher doses. As a result, WADA has prohibited the use of these drugs in sports. Exceptions are formoterol, salbutamol, fenoterol, salmeterol and terbutaline which can be used by athletes if a proper medical justification (TUE) is issued. Although this group of medication is frequently declared by athletes on the doping control forms these substances are not always detected. In addition, no minimum required performance levels (MRPL) for laboratories have been presently issued by WADA. Information about the excretion of beta-2-agonists in urine after the use by different administration routes could result in the establishment of MRPL levels based upon scientific evidence. Therefore this project will focus on the administration of different beta-2-agonists by different administration routes. In this project 5 beta-2-agonists will be administered (i.e. salbutamol, formoterol, fenoterol, salmeterol and terbutaline) of which 2 of them will be administered both by inhalation and orally. All these studies will be conducted following a strict research protocol as approved by an ethical committee. As the supposed outcome of this research is a MRPL level, the first step of this project is to develop and validate quantitative analytical methods for all administered beta-2-agonists (except salbutamol for which these methods already exist).
    [Show full text]
  • Dry Powder Inhalers Comprising a Carrier Other Than Lactose
    (19) TZZ Z T (11) EP 2 682 097 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.01.2014 Bulletin 2014/02 A61K 9/00 (2006.01) A61K 9/14 (2006.01) A61K 31/40 (2006.01) A61K 31/439 (2006.01) (2006.01) (21) Application number: 13175077.0 A61K 31/4704 (22) Date of filing: 04.07.2013 (84) Designated Contracting States: • Türkyilmaz, Ali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 34460 Istanbul (TR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Mutlu, Onur PL PT RO RS SE SI SK SM TR 34460 Istanbul (TR) Designated Extension States: BA ME (74) Representative: Sevinç, Erkan Istanbul Patent & Trademark (30) Priority: 05.07.2012 TR 201207842 Consultancy Ltd. Plaza 33, Buyukdere Cad. No: 33/16 (71) Applicant: Arven Ilac Sanayi Ve Ticaret A.S. Sisli Istanbul 34460 (TR) 34381 Istanbul (TR) (72) Inventors: • Cifter, Ümit 34460 Istanbul (TR) (54) Dry Powder Inhalers Comprising A Carrier Other Than Lactose (57) This invention relates to novel pharmaceutical other obstructive airways diseases. In addition, the compositions for inhalation comprising separately, se- present invention relates to novel pharmaceutical com- quentially or together, drugs having amine in the form of position for inhalation based on combinations of long act- a dry powder in admixture with a pharmaceutically ac- ing muscarinic antagonists, long acting beta agonists, ceptable carrier, other than lactose, and its use in the short acting beta-2 agonists, corticosteroids or a combi- treatment of respiratory condition selected from asthma nation of two or more of them.
    [Show full text]
  • Fenoterol Hydrobromide May Be Given from a Фенотерол of Short-Acting Beta2 Agonists in the Previous 1 to 5 Years
    Clenbuterol Hydrochloride/Fenoterol 1121 struction. Etamiphylline does not liberate theophylline in the Adverse Effects and Precautions 11. Sears MR, Taylor DR. The β -agonist controversy: observa- body. Etamiphylline camsilate is used in veterinary medicine. tions, explanations and relationship to asthma epidemiology. As for Salbutamol, p.1131. Drug Safety 1994; 11: 259–83. The hydrochloride salt has also been used. 12. Fuller RW. Use of β agonists in asthma: much ado about noth- Increased mortality. Since the introduction of metered-dose ing? BMJ 1994; 309: 795–6. Preparations aerosols of beta agonists there have been two reported epidemics 13. Sears MR. Asthma deaths in New Zealand. Lancet 1995; 345: Proprietary Preparations (details are given in Part 3) of increased morbidity and mortality in asthmatic patients asso- 655–6. Spain: Solufilina. ciated with their use. The first occurred in the 1960s and was 14. Tattersfield AE. Use of β agonists in asthma: much ado about linked with the use of high-dose isoprenaline inhalers.1 The use nothing? BMJ 1994; 309: 794–5. 15. Lanes SF, et al. Respiratory medications and risk of asthma of isoprenaline was subsequently largely stopped in favour of death. Thorax 2002; 57: 683–6. more selective beta2 agonists. 16. Anderson HR, et al. Bronchodilator treatment and deaths from Etofylline (BAN, rINN) The second epidemic occurred in New Zealand in the late 1970s asthma: case-control study. Abridged version: BMJ 2005; 330: 1-5 117. Full version: http://www.bmj.com/cgi/reprint/330/7483/117 Aethophyllinum; Etofilina; Etofilinas; Etofillin; Etofylin; Etofylliini; and 1980s and was associated with the use of fenoterol.
    [Show full text]
  • Multi-Discipline Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210595Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multi‐disciplinary Review and Evaluation {NDA 210595} {Duaklir Pressair, Aclidinium Bromide/Formoterol Fumarate inhalation powder} NDA/BLA Multi‐Disciplinary Review and Evaluation Application Type NDA Application Number(s) 210595 Priority or Standard Standard Submit Date(s) May 31, 2018 Received Date(s) May 31, 2018 PDUFA Goal Date March 31, 2019 Division/Office Division of Pulmonary, Allergy, and Rheumatology Products Review Completion Date March 29, 2019 Established/Proper Name Aclidinium bromide/formoterol fumarate inhalation powder (Proposed) Trade Name Duaklir Pressair Pharmacologic Class Long‐acting muscarinic/Long‐acting B2‐agonist Code name Applicant AstraZenecaPharmaceuticals LP Doseage form Inhalation powder Applicant proposed Dosing One inhalation (400 µg aclidinium bromide/ 12 µg formoterol Regimen fumarate) twice daily Applicant Proposed ‐ (b) (4) maintenance treatment of (b) (4) Indication(s)/Population(s) patients with chronic obstructive pulmonary disease (COPD), (b) (4) Recommendation on Approval Regulatory Action Recommended (b) (4) maintenance treatment of patients with COPD Indication(s)/Population(s) (if applicable) Recommended Dosing One inhalation (400 µg aclidinium bromide/ 12 µg formoterol Regimen fumarate) twice daily 1 Version date: September 12, 2018 Reference
    [Show full text]
  • List Item Short-Acting Beta-Agonists Article-31 Referral
    Annex II Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation 19 Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation The CMDh considered the below PRAC recommendation dated 5 September 2013 with regards to the terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol and isoxsuprine containing medicinal products: 1. Overall summary of the scientific evaluation of terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol and isoxsuprine containing medicinal products by PRAC (see Annex I) On 27 November 2012, further to evaluation of data resulting from pharmacovigilance activities, Hungary informed the European Medicines Agency, pursuant to Article 31 of Directive 2001/83/EC, of their consideration that the risk-benefit balance of short-acting beta-agonists (SABAs) containing medicinal products authorised in obstetric indications has become unfavourable, taking into account the cardiovascular events reported. Hungary considered it was in the interest of the Union to refer the matter to the PRAC and expressed concerns with regards to the posology and warnings reflected in the product information. The short-acting beta-agonists (SABAs) (also known as beta-mimetics), salbutamol, terbutaline, fenoterol, ritodrine, hexoprenaline and isoxsuprine are all nationally authorised and have been on the market within the EU since the 1960s. Authorised obstetric indications for SABAs differ across Member States. The authorised obstetric indications include partus prematurus, tocolysis (for some products use is restricted to particular weeks of gestation but for others no specific gestation period is specified), external cephalic version (ECV), and hyper-uterine contractility.
    [Show full text]
  • Interactions Between Corticosteroids and Β Agonists
    Thorax 2000;55:595–602 595 Occasional reviews Interactions between corticosteroids and â agonists Department of Medicine, Dunedin D R Taylor, R J Hancox School of Medicine, P O Box 913, Dunedin, New Zealand D R Taylor Inhaled corticosteroids and â agonists are the whereas long acting agents are indicated as a R J Hancox most frequently prescribed drugs in the supplement to anti-inflammatory therapy if management of chronic asthma. Current breakthrough symptoms persist.1 Thus, co- Correspondence to: prescribing is commonplace. However, despite Dr D R Taylor guidelines emphasise their complementary e-mail: robin.taylor@ role. Inhaled corticosteroids are the treatment dynamic interactions between endogenous stonebow.otago.ac.nz of choice for all but the mildest of disease. glucocorticoids and catecholamines in vivo, it Received 5 January 2000 Short acting â agonists are recommended for is only recently that interest in the possibility of Accepted for publication “as required” relief of asthma symptoms, drug interactions has developed. Two topical 20 January 2000 and clinically relevant questions arise. Firstly, do positive interactions occur, thus providing s BA theoretical justification for current trends to use combination products incorporating a long Gs BR acting â agonist and a corticosteroid? Sec- AC ondly, do negative interactions occur which might explain the apparent paradox that, HSP GR 1 ATP despite increasing use of the two therapies over the last 30 years, the overall burden of asthma cAMP HSP s 2 morbidity in most western countries has GR CREB continued to increase?2 TF 3 EVects of glucocorticoids on â receptor PKA 10 function s 4 Endogenous adrenal glucocorticoids have an GR CREB important facilitatory eVect on â receptor 6 function in vivo.
    [Show full text]
  • Inhaled Β2-Agonists in Asthma Management: an Evolving Story
    Diana Silva1,2, Tiago Jacinto3,4 [email protected] 1Serviço de Imunoalergologia, Centro Hospitalar São João, EPE, Porto, Portugal. 2Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal. 3Allergology, CUF Porto Hospital and Instituto, Porto, Portugal. 4CINTESIS – Center for Research in Health Technologies and Information Systems, Faculty of Medicine, University of Porto, Porto, Portugal. Inhaled β2-agonists in asthma management: an evolving story Cite as: Silva D, Jacinto T. Inhaled β2-agonists in asthma Landmark papers in respiratory medicine management: an evolving story. Breathe 2016; 12: 379–381. From the beginning… was inadequate for control of nocturnal symptoms and limited their use for maintenance treatment [1]. Sympathomimetic agents have been known in For these reasons, long-acting β2-agonists (LABA) Chinese medicine for at least 5000 years as a drug were developed in the 1980s. to treat disorders of respiratory tract; however, they With duration of action that reached 12 h, were introduced to western medicine mainly in the formoterol and salmeterol were considered for beginning of the 20th century [1]. long-term treatment, particularly among patients Adrenaline and isoproterenol were the first who did not achieve control under regular inhaled to be introduced, although, being unselective corticosteroids. The mechanisms for their long β-agonists, they were prone to significant side- duration have been debated, and it seems that effects. Through the years, new formulations and different physicochemical properties in contact routes of administration of these drugs, namely with the cell membrane and with the β2-receptor the inhaled route, were associated with more might explain their characteristics.
    [Show full text]